An observational study in Stargardt Disease, sponsored by Nanoscope Therapeutics Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Nanoscope Therapeutics Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.
Among the 42 studies in Stargardt Disease with a site in United States, this one is the 15th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2023, is one of 16 observational ones, reaches primary completion later than 5 of the 24 other live ones, and was the 26th registered.
68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.
Browse Stargardt Disease studies →16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
Alkeus Pharmaceuticals, Inc. · Sites in United States
Ages 8–45
Cellio Therapeutics Inc · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 6+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 16 · Phase 3 5
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6 is below the median of 50 across 25 observational studies indexed under Stargardt Disease.
Median enrollment 41 across the 26 interventional studies, 63 across the 16 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 42 have an industry lead sponsor. The 10 most frequent:
Nanoscope Therapeutics Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Nanoscope Therapeutics Inc. has 3 studies filed under Stargardt Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Stargardt Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06435000Splice BioAn Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene | 2026-12 |
| NCT07502664Ray Therapeutics, Inc.Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) | 2027-02 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
| NCT06591806AAVantgarde Bio SrlAn Observational Study in Children and Adults With Stargardt Disease | 2027-06-30 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Stargardt Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
This study is designed to follow subjects with Stargardt Disease (SD) previously enrolled in study NTXMCO-004 (STARLIGHT, NCT05417126). In that study, all 6 enrolled subjects received MCO-010, an ambient light-activated, Multi-Characteristic Opsin (MCO) transgene in an adeno-associated virus serotype 2 (AAV2) vector via intravitreal injection (IVT). MCO-010 has the potential to restore vision irrespective of the underlying gene mutation, and because it is directed at bipolar retinal cells, intact photoreceptors are not required. Further details on MCO-010 and the underlying disease under investigation are included in the protocol for STARLIGHT and are not repeated herein
The study population eligible to participate will comprise of the 6 subjects previously enrolled in STARLIGHT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects are eligible to be included in the study only if all of the following criteria apply:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
Assessment of the long-term safety profile of a single intravitreal injection of MCO-010
Assessment of incidences, nature, and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs); intraocular inflammation graded through ocular exam; clinical examination, and intraocular pressure.
Time frame: 204 weeks
Evaluation of the long-term effects on visual acuity of a single intravitreal injection of MCO-010; 1.2E11 gc/eye
Change from baseline in BCVA over time in the study eye and fellow eye
Time frame: 204 weeks
Exploration of the long-term impact of MCO-010 on retinal anatomy
Assessment of fundus photography and optical coherence tomography (OCT) outcomes over time
Time frame: 204 weeks
Assessment of the long-term durability of MCO-010 induced on gene reporter expression
Change from baseline of fundus fluorescence intensity of reporter (mCherry) over time in the study eye and fellow eye
Time frame: 204 weeks
Plan to share: Yes — The results of the clinical trial will be made available when the study is completed. The results will be published on this site and be available to conference presentations and publications.
Time frame: Within a year from the long term monitoring data availability
Access criteria: IPD sharing access will be subject to data transfer agreement. IPD generated as part of this clinical study may be subject to patient confidentiality.
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for May 2027, 43 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanoscope Therapeutics Inc.